GPX1 and chronic myelogenous leukemia, BCR-ABL1 positive: These data therefore raise the possibility that GPx-1 induction by Bcr-Abl inhibition may have a detrimental effect on the efficacy of treatment, as well as the efficacy of approaches to treat CML once resistance to front line therapy has failed.